Myriad Genetics Stock
Price
Target price
€24.20
€24.20
-0.820%
-0.2
-0.820%
€22.15
19.07.24 / Stuttgart Stock Exchange
WKN: 897518 / Symbol: MYGN / Name: Myriad Genetics / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Myriad Genetics Stock
The price for the Myriad Genetics stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.820%).
With 4 Buy predictions and 3 Sell predictions the community is currently undecided on Myriad Genetics.
However, we have a potential of -9.09% for Myriad Genetics as the target price of 22 € is below the current price of 24.2 €.
Pros and Cons of Myriad Genetics in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | -0.820% | 0.000% | 9.009% | 16.346% | 36.723% | -8.783% | 0.833% |
| Integer Hldg | - | 1.818% | 4.673% | 45.455% | 25.843% | 47.368% | 54.440% |
| Healthequity Inc. | 0.710% | 2.899% | -8.387% | 26.786% | 19.328% | 12.734% | - |
| Omnicell Inc. | -0.790% | 3.306% | -5.303% | -55.752% | -28.571% | -80.469% | -59.050% |
Comments
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "underperform" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $20.00 price target on the stock, down previously from $25.00.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $35.00 price target on the stock, up previously from $25.00.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat